Small Cell Carcinoma Clinical Trials

108 recruitingLast updated: June 21, 2026

There are 108 actively recruiting small cell carcinoma clinical trials across 36 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3, Early Phase 1, Phase 4. Top locations include Columbus, Ohio, United States, Chicago, Illinois, United States, St Louis, Missouri, United States. Updated daily from ClinicalTrials.gov.


Small Cell Carcinoma Trials at a Glance

108 actively recruiting trials for small cell carcinoma are listed on ClinicalTrialsFinder across 6 cities in 36 countries. The largest study group is Phase 2 with 46 trials, with the heaviest enrollment activity in Columbus, Chicago, and St Louis. Lead sponsors running small cell carcinoma studies include National Cancer Institute (NCI), Mayo Clinic, and City of Hope Medical Center.

Browse small cell carcinoma trials by phase

Treatments under study

About Small Cell Carcinoma Clinical Trials

Looking for clinical trials for Small Cell Carcinoma? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Small Cell Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Small Cell Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 108 trials

Recruiting
Phase 3

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Stage IIIB Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8Advanced Lung Non-Squamous Non-Small Cell Carcinoma+2 more
National Cancer Institute (NCI)300 enrolled603 locationsNCT04181060
Recruiting
Phase 3

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Stage IIIA Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Lung Non-Small Cell Carcinoma+1 more
National Cancer Institute (NCI)306 enrolled245 locationsNCT06498635
Recruiting
Phase 3

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Stage IIIA Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Lung Non-Small Cell Carcinoma+3 more
National Cancer Institute (NCI)1,210 enrolled1150 locationsNCT04267848
Recruiting
Phase 3

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

Stage IIIB Lung Cancer AJCC v8Stage IIIC Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8+1 more
National Cancer Institute (NCI)304 enrolled319 locationsNCT06096844
Recruiting
Phase 1Phase 2

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Colorectal, CancerColorectal CarcinomaNon-small Cell Lung Cancer+29 more
Institut de Recherches Internationales Servier554 enrolled27 locationsNCT05786924
Recruiting
Phase 1

MOv19-BBz CAR T Cells in FRa+ Cancers

Recurrent Lung Non-Small Cell CarcinomaMetastatic Non Small Cell Lung Cancer
University of Pennsylvania10 enrolled1 locationNCT07116057
Recruiting
Phase 2Phase 3

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

Extensive Stage Lung Small Cell Carcinoma
National Cancer Institute (NCI)138 enrolled416 locationsNCT04402788
Recruiting
Phase 2

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

Lung Non-Small Cell Carcinoma
Alliance for Clinical Trials in Oncology164 enrolled28 locationsNCT07293247
Recruiting
Phase 2

Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer

Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast CarcinomaMetastatic Lung Non-Small Cell Carcinoma+2 more
University of Washington22 enrolled2 locationsNCT06518057
Recruiting
Phase 2

SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer

Metastatic Lung Non-Small Cell CarcinomaStage IIIC Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8+1 more
University of Washington30 enrolled1 locationNCT05570825
Recruiting
Phase 2

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

Recurrent Lung Non-Small Cell CarcinomaAdvanced Lung Non-Small Cell CarcinomaStage IIIB Lung Non-Small Cell Cancer AJCC v7+1 more
National Cancer Institute (NCI)46 enrolled345 locationsNCT03191149
Recruiting
Phase 1Phase 2

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

Stage IV Lung Cancer AJCC v8Extensive Stage Lung Small Cell Carcinoma
National Cancer Institute (NCI)45 enrolled43 locationsNCT06287775
Recruiting
Phase 4

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

Metastatic Head and Neck Squamous Cell CarcinomaMetastatic Hepatocellular CarcinomaMetastatic Lung Non-Small Cell Carcinoma+18 more
OHSU Knight Cancer Institute160 enrolled1 locationNCT07405086
Recruiting
Phase 2

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

Stage III Lung Cancer AJCC v8Lung AdenocarcinomaLung Non-Squamous Non-Small Cell Carcinoma+1 more
National Cancer Institute (NCI)42 enrolled34 locationsNCT05198830
Recruiting
Phase 1

Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

Gastric CancerHead and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)+9 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.40 enrolled3 locationsNCT07517198
Recruiting
Phase 2

Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

Urothelial CarcinomaEsophageal CarcinomaHepatocellular Carcinoma+28 more
Mayo Clinic50 enrolled1 locationNCT06265285
Recruiting
Phase 2

Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)

Small Cell Carcinoma of the BladderHigh Grade Neuroendocrine Tumors of the Urinary Tract
National Cancer Institute (NCI)45 enrolled1 locationNCT06228066
Recruiting
Phase 2

Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...

Small Cell Carcinoma of the BladderSmall Cell Carcinoma of the Urinary TractSquamous Cell Carcinoma of the Bladder+5 more
National Cancer Institute (NCI)60 enrolled1 locationNCT06161532
Recruiting
Phase 2

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Stage IV Lung Cancer AJCC v8Recurrent Lung Non-Small Cell Carcinoma
SWOG Cancer Research Network66 enrolled454 locationsNCT05642572
Recruiting
Phase 3

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

Stage IIIA Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Resectable Lung Non-Small Cell Carcinoma+1 more
Alliance for Clinical Trials in Oncology1,100 enrolled378 locationsNCT06632327